More aggressive prostate cancers are associated with loss-of-function alterations in the BRCA1 and BRCA2 genes and a major sensitivity to PARP inhibition has observed and analyzed in the study of de Bono and colleagues [63]. The gene discussed is BRCA1; the disease is prostate carcinoma.